Greenland Mines Ltd (GRML) stock
GRMLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as GRMLW
$2.99+0.08 (+2.75%)
Close on Nov 20, 2026Market cap $40.92MP/E –Yield –
Greenland Mines r&d expenses
Research and development expenses are spending on new products and technology.
Greenland Mines's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.26M, up 145.2% year over year. For fiscal 2025 it was $634.19K.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $634.19K | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $409.52K | +49.8% |
| Q2 FY2026 | Jun 30, 2026 | $400.54K | +67.8% |
| Q1 FY2026 | Mar 31, 2026 | $321.27K | – |
| Q4 FY2025 | Dec 31, 2025 | $124.34K | – |
| Q3 FY2025 | Sep 30, 2025 | $273.31K | – |
| Q2 FY2025 | Jun 30, 2025 | $238.70K | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?